Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 10:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Not applicable Interventional Accepts healthy volunteers Results available

Interaction Between Cannabidiol, Meal Ingestion, and Liver Function

NCT04971837
Conditions
Metabolism, Liver Function, Pharmacokinetics
Interventions
Cannabidiol (CBD) powder formulation, Cannabidiol (CBD) Oil based tincture formulation, Cannabidiol (CBD) Gum Arabic, maltodextrin base formulation, Cannabidiol (CBD) Gum Arabic, sorbitol base formulation, Cannabidiol (CBD) Isolate in water formulation, CBD matching Placebo
Dietary Supplement
Lead sponsor
Colorado State University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Fort Collins, Colorado
Conditions
Recurrent Pericarditis
Interventions
CardiolRx
Drug
Lead sponsor
Cardiol Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 16 more
Conditions
Multiple Sclerosis, Sleep, Pain
Interventions
Cannabidiol (CBD), Tetrahydrocannabinol (THC), Placebo CBD, Placebo THC
Drug
Lead sponsor
Tiffany J. Braley, MD, MS
Other
Eligibility
18 Years to 65 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed Not applicable Interventional Accepts healthy volunteers

Cannabidiol and Focus Study (CBD-Focus)

NCT05189275
Conditions
Healthy
Interventions
Daily Beverage Intervention
Dietary Supplement
Lead sponsor
University of Northern Colorado
Other
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Greeley, Colorado
Completed Not applicable Interventional Accepts healthy volunteers

Influence of Cannabidiol on Glucose Tolerance and The Gut Microbiota

NCT05285449
Conditions
Diabetes
Interventions
Cannabidiol (CBD) powder formulation, Matching Placebo Cannabidiol (CBD) powder formulation
Dietary Supplement
Lead sponsor
Christopher Bell
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Fort Collins, Colorado
Conditions
Prader-Willi Syndrome
Interventions
RAD011, Placebo
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
8 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • Iowa City, Iowa + 5 more
Conditions
Gastroparesis, Dyspepsia
Interventions
Cannabidiol, placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Autism Spectrum Disorder
Interventions
GWP42003-P, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 9 more
Completed Phase 1Phase 2 Interventional Results available

Trial of Cannabis for Essential Tremor

NCT03805750
Conditions
Essential Tremor
Interventions
CBD/THC, Placebo oral capsule
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
La Jolla, California
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence

NCT01468012
Conditions
Cocaine Dependence
Interventions
levodopa carbidopa and entacapone (LCE), Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Seizures Associated With EMAS
Interventions
GWP42003-P, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 7 more
Conditions
Multiple Sclerosis (MS)
Interventions
Nabiximols, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Port Charlotte, Florida • Tampa, Florida + 11 more
Completed Not applicable Interventional Accepts healthy volunteers

CBD, Immune Function, and Neural Health

NCT04881539
Conditions
Healthy
Interventions
Cannabidiol (CBD)
Dietary Supplement
Lead sponsor
University of Northern Colorado
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Greeley, Colorado
Conditions
Opioid-use Disorder
Interventions
Cannabidiol 100 MG/ML [Epidiolex], Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
Boston, Massachusetts • Rutland, Vermont
Conditions
Idiopathic Parkinson's Disease
Interventions
IPX054 200 mg, IPX054 250 mg, CD-LD IR, CD-LD CR, IPX054 200 mg Placebo, IPX054 250 mg Placebo, CD-LD IR Placebo, CD-LD CR Placebo
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Bingham Farms, Michigan • Portland, Oregon
Conditions
Fragile X Syndrome, Fragile X Syndrome (FXS)
Interventions
ZYN002, Placebo
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
3 Years to 29 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Culver City, California • Irvine, California + 15 more
Conditions
Alcohol Use Disorder
Interventions
Full-Spectrum Cannabidiol (CBD), Broad-Spectrum Cannabidiol (CBD), Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Epilepsy, Lennox-Gastaut Syndrome
Interventions
GWP42003-P 20 mg/kg/day Dose, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 55 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
17
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 14 more
Conditions
Pain
Interventions
Active CBD/THC Dose 1, Active CBD/THC Dose 2, matched placebo comparator
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 68 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Phase 4 Interventional Results available

DTA (Dopaminergic Therapy for Anhedonia) Study

NCT04723147
Conditions
Depression, Anhedonia
Interventions
Carbidopa Levodopa, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
25 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Completed Phase 2 Interventional Accepts healthy volunteers

Levodopa for Diabetic Retinopathy

NCT07444892
Conditions
Diabetic Retinopathy
Interventions
Levodopa, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Decatur, Georgia
Conditions
Spasticity With Multiple Sclerosis
Interventions
Nabiximols, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Denver, Colorado • Naples, Florida • Tampa, Florida + 3 more
Completed Phase 2 Interventional Accepts healthy volunteers

Dopaminergic Dysfunction in Late-Life Depression

NCT04469959
Conditions
Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant, Levodopa, Gait Impairment
Interventions
L-Dopa, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Nashville, Tennessee
Conditions
Treatment Resistant Depression
Interventions
Active study drug ( oral CBD), matching placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Birmingham, Alabama